Title:Nano-approaches and Recent Advancements in Strategies to Combat Challenges Associated with Thyroid Cancer Therapies
Volume: 19
Issue: 3
Author(s): Gurmehar Singh, Jatin Rathee, Triveni, Neha Jain*, Upendra Nagaich, Shreya Kaul, Manisha Pandey*Bapi Gorain
Affiliation:
- Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Noida, U.P., India
- Department of
Pharmaceutical Sciences, Central University of Haryana, Mahendergarh, 123031, India
Keywords:
Nanotechnology, nanocarriers, screening techniques, target-specific therapy, thyroid cancer, DNA-damaging model, conventional delivery.
Abstract: The prevalence of thyroid cancer (TC) is more common in women and is up to 43% in patients
aged between 45-65 years. The battle against TC is hampered by the lack of effective diagnostic
and therapeutic approaches. The effectiveness of surgical procedures, such as thyroidectomy and
nutraceutical treatments, are accompanied by several difficulties and still require further research. Alternatively,
the DNA-damaging traditional model of chemotherapy is linked to poor solubility, untoward
systemic effects, and associated cytotoxicity, instituting an urgent need to establish a specialized,
factual, and reliable delivery tool. In order to overcome the limitations of conventional delivery
systems, nanotechnology-based delivery tools have shown the potential of articulating endless inherent
implementations. The probable benefits of emerging nanotechnology-based diagnostic techniques
include rapid screening and early illness diagnosis, which draws investigators to investigate and assess
the possibility of this treatment for TC. Subsequently, organic (e.g., liposomes, polymer-based,
and dendrimers) and inorganic (e.g., gold, carbon-based, mesoporous silica, magnetic, and quantum
dots) NPs and hybrids thereof (liposome-silica, chitosan-carbon, and cell membrane-coated) have
been projected for TC biomarker screening, therapy, and detection, providing better outcomes than
traditional diagnostic and treatment techniques. Therefore, this review aims to offer a broad perspective
on nanoplatform in TC, accompanied by present and potential future treatment options and
screening techniques; including the innovative patents utilized in the realm of thyroid cancer using
nanocarriers. The goal of cancer therapy has traditionally been to "search a thorn in a hayloft"; therefore,
this article raises the possibility of treating TC using nano-oncotherapeutics, which might be
useful clinically and will encourage future researchers to explore this tool’s potential and drawbacks.
